Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Pritelivir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pritelivir Shows Superior Ph 3 Efficacy in HIV Patients with HSV
    Pritelivir Shows Superior Ph 3 Efficacy in HIV Patients with HSV

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244926/0/en/Pritelivir-Demonstrates-Superior-Efficacy-in-People-Living-with-HIV-with-Refractory-HSV-in-Phase-3-PRIOH-1.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    1. Aicuris Shows Positive Ph 3 Data for Pritelivir at TANDEM
    1. Aicuris Shows Positive Ph 3 Data for Pritelivir at TANDEM

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232727/0/en/Aicuris-Presents-Positive-Phase-3-Data-for-Pritelivir-in-Immunocompromised-Patients-with-Refractory-Herpes-Simplex-Virus-at-TANDEM.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Aicuris To Present Pritelivir Phase 3 HSV Data At Tandem
    Aicuris To Present Pritelivir Phase 3 HSV Data At Tandem

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228292/0/en/Aicuris-Announces-Pritelivir-Phase-3-HSV-Data-to-Be-Presented-as-Late-Breaking-Oral-Presentation-at-Tandem.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Aicuris Reveals Pritelivir Phase 2 Success And AIC468 Safety Data
    Aicuris Reveals Pritelivir Phase 2 Success And AIC468 Safety Data

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169156/0/en/Aicuris-Presents-Positive-Phase-2-Results-for-Pritelivir-and-Favorable-Phase-1-Safety-Data-for-AIC468-at-ID-Week-2025.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    Aicuris’ Pritelivir Meets Ph3 Endpoint in Refractory HSV
    Aicuris’ Pritelivir Meets Ph3 Endpoint in Refractory HSV

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167679/0/en/Aicuris-Announces-Pritelivir-Met-Primary-Endpoint-in-Immunocompromised-Patients-with-Refractory-Herpes-Simplex-Virus-in-Phase-3-Pivotal-Trial.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    Aicuris to Present Orally and via Poster at ID Week 2025
    Aicuris to Present Orally and via Poster at ID Week 2025

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150566/0/en/Aicuris-Announces-Upcoming-Oral-and-Poster-Presentations-at-ID-Week-2025.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.